SCHEMBL2186972

SCHEMBL2186972

CCNC(=O)c1nc(Cl)sc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.51
NPC1 O15118 1/20 0.51
PIN1 Q13526 1/20 0.50
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HSP90AB1 P08238 2/20 0.44
NPSR1 Q6W5P4 2/20 0.42
GAA P10253 2/20 0.41
HTT P42858 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
LMNA P02545 1/20 0.40
ABL1 P00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9586464 0.85 HDAC3 (0.44) HPGDNPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2187339 0.84 HPGD (0.52) HPGDNPC1PIN1ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL9586477 0.83 PMP22 (0.46) HPGDALDH1A1KDM4ESMN1; SMN2HSD17B10
SCHEMBL3315030 0.79 KDM4E (0.50) HPGDPIN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL10432561 0.79 HDAC3 (0.41) HPGDALDH1A1KDM4ESMN1; SMN2HSD17B10
SCHEMBL9587190 0.78 KDM4E (0.69) HPGDALDH1A1KDM4ESMN1; SMN2HSD17B10
SCHEMBL3321548 0.78 GRM6 (0.58) HPGDNPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL7224987 0.73 HDAC4 (0.36) HPGDNPC1PIN1ALDH1A1KDM4E
SCHEMBL9586953 0.73 CYP1A2 (0.51) KDM4ESMN1; SMN2NPSR1GAALMNA
SCHEMBL20780956 0.72 ALDH1A1 (0.47) HPGDNPC1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 HPGD 3481/4885NPC1 1296/4885PIN1 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.